These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus. Gloux K; Guillemet M; Soler C; Morvan C; Halpern D; Pourcel C; Vu Thien H; Lamberet G; Gruss A Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193654 [TBL] [Abstract][Full Text] [Related]
3. Isolation of Lipoprotein Particles from Chicken Egg Yolk for the Study of Bacterial Pathogen Fatty Acid Incorporation into Membrane Phospholipids. Delekta PC; Lydic TA; Hammer ND J Vis Exp; 2019 May; (147):. PubMed ID: 31157784 [TBL] [Abstract][Full Text] [Related]
8. Elucidating the Impact of Bacterial Lipases, Human Serum Albumin, and FASII Inhibition on the Utilization of Exogenous Fatty Acids by Pruitt EL; Zhang R; Ross DH; Ashford NK; Chen X; Alonzo F; Bush MF; Werth BJ; Xu L bioRxiv; 2023 Jun; ():. PubMed ID: 37425828 [No Abstract] [Full Text] [Related]
9. A FASII Inhibitor Prevents Staphylococcal Evasion of Daptomycin by Inhibiting Phospholipid Decoy Production. Pee CJE; Pader V; Ledger EVK; Edwards AM Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718253 [TBL] [Abstract][Full Text] [Related]
12. Host Fatty Acid Utilization by Staphylococcus aureus at the Infection Site. Frank MW; Yao J; Batte JL; Gullett JM; Subramanian C; Rosch JW; Rock CO mBio; 2020 May; 11(3):. PubMed ID: 32430471 [No Abstract] [Full Text] [Related]
13. Elucidating the impact of bacterial lipases, human serum albumin, and FASII inhibition on the utilization of exogenous fatty acids by Pruitt EL; Zhang R; Ross DH; Ashford NK; Chen X; Alonzo F; Bush MF; Werth BJ; Xu L mSphere; 2023 Dec; 8(6):e0036823. PubMed ID: 38014966 [TBL] [Abstract][Full Text] [Related]
14. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Parsons JB; Frank MW; Subramanian C; Saenkham P; Rock CO Proc Natl Acad Sci U S A; 2011 Sep; 108(37):15378-83. PubMed ID: 21876172 [TBL] [Abstract][Full Text] [Related]
15. Complestatin exerts antibacterial activity by the inhibition of fatty acid synthesis. Kwon YJ; Kim HJ; Kim WG Biol Pharm Bull; 2015; 38(5):715-21. PubMed ID: 25947917 [TBL] [Abstract][Full Text] [Related]
16. How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics. Yao J; Rock CO J Biol Chem; 2015 Mar; 290(10):5940-6. PubMed ID: 25648887 [TBL] [Abstract][Full Text] [Related]